For nearly 10 years, more women than men received PhDs in the biomedical sciences, yet women are still underrepresented at every subsequent stage of academic advancement. In 2015, for example, women earned 53% of PhDs, but they comprised only 48% of post-doctoral fellows, 44% of assistant professors, and 35% of professors. To better understand what might be contributing to women’s underrepresentation in later stages of academia, Dr. Lisa Hechtman and her colleagues at the National Institute of General Medical Sciences (NIGMS) analyzed “funding longevity by gender” among funded NIH investigators. Their analysis, recently published in the Proceedings of the National Academy of Sciences, yielded a number of interesting findings which I’d like to share with you.
We have written several blogs and articles over the past two years about our efforts to enhance stewardship and transparency in clinical trial research. Indeed, earlier this year Congress applauded our efforts thus far and reaffirmed its commitment to ensuring public access to the results of the NIH-funded clinical trials through timely registration and results information reporting on ClinicalTrials.gov. However, we have heard concern about how the NIH’s Policy on the Dissemination of NIH-Funded Clinical Trial Information applies to fundamental studies involving human participants.
We recently released a policy notice announcing that as of September 26, 2018, the NIH will no longer be offering the Protecting Human Research Participants (PHRP) course. It is important to note that investigators are still required to comply with all aspects of the NIH policy Required Education in the Protection of Human Research Participants, and can do so through a different training program or course.
On Friday, Sept. 14, General Registration Rates end for this valuable and unique learning opportunity, designed for those new to working with the NIH grants process. If you are interested in attending the Fall NIH Regional Seminar in San Francisco, CA (Oct. 17-19) and have not registered yet, then now is the time!
A new resource, RPPRs: Who Can Do What? provides a quick look at the Annual, Interim, and Final Research Performance Progress Reports (RPPRs), including information such as due dates and how to access RPPR links. It also charts what happens to the Interim RPPR when a Type 2, Competing Renewal application is submitted.
For decades, NIH has required valid analysis, also known as stratified analysis, to explore how well interventions work across sex/gender and race/ethnicity for all applicable clinical trials. After revising the policy last year, NIH now requires the findings from these stratified analyses to be reported on ClinicalTrials.gov after an applicable NIH-Defined Phase III clinical trial has completed. Wondering about how this impacts your research?